Cormorant Asset Management »

Enliven Therapeutics shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $4.1M 200k 20.47
2025-06-30 $4.0M 200k 20.06
2025-03-31 $4.9M 250k 19.68
2024-12-31 $5.6M 250k 22.50
2023-09-30 $17M 1.2M 13.66
2023-06-30 $40M 1.9M 20.41
2023-03-31 $42M 1.9M 21.90

More positions owned by Cormorant Asset Management

Bridgebio Oncology Therapeut Com New
Abivax Sa Sponsored Ads (ABVX)
Eyepoint Pharmaceuticals Com New (EYPT)
Rapport Therapeutics (RAPP)
Bridgebio Pharma (BBIO)
Edgewise Therapeutics (EWTX)
Bright Minds Biosciences Com New (DRUG)
Arcellx Common Stock (ACLX)
Insmed Com Par $.01 (INSM)
Newamsterdam Pharma Company Ordinary Shares (NAMS)
Praxis Precision Medicines I Com New (PRAX)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Pharvaris N V (PHVS)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Gh Research Ordinary Shares (GHRS)

View all positions for Cormorant Asset Management

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
Commodore Capital
Fairmount Funds Management
BlackRock
VR Adviser
Polar Capital Holdings
Vanguard Group
Henderson Group
Novo A/S
Pictet Asset Management Holding SA
Blackstone Group
Capital Research Global Investors
Citadel Advisors
Vestal Point Capital

View all funds holding Enliven Therapeutics